Tuesday, July 1, 2025 7/1/2025

Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment

Award Number: UH3OD023289
ORGANIZATION: OFFICE OF THE DIRECTOR, NIH
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/21/2016
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment - We propose continued follow-up of our large ECHO ELEGANT cohort (n=2130) and to lead collaborative ECHO Cohort science. Our scientific aims focus on child obesity and adverse neurodevelopment, two common and increasingly prevalent conditions. Our comprehensive planned analyses take advantage of the core longitudinal data collected via the ECHO Cohort Protocol during the initial phase and the new phase. In Aim 1, we will assess the role of in-utero exposure to endocrine disrupting compounds (EDC) on child growth (growth trajectory), adiposity (body fat mass), obesity (body mass index [BMI]) and neurodevelopment (autism, autism-related traits, and emotional-behavioral development [ND]), by addressing solution oriented scientific questions that may promote precision interventions, practice recommendations and policies. We will clarify the effects of two understudied classes of EDCs (perfluoroalkyl substances (PFAS) and contemporary organophosphate ester flame retardants (OPE)) and increase understanding of real-world exposure scenarios by examining individual and joint effects. In Aim 2, we will clarify the joint effects of multiple maternal prenatal overnutrition factors (high dietary energy intake/poor diet quality, high pre-conception BMI, excessive gestational weight gain, gestational diabetes/diabetes) on child growth, adiposity, obesity, and ND. While likely to co-occur, human studies on their joint effects on childhood obesity and ND are sparse. Since child growth and development are dynamic processes, we will address the proposed associations at different ages of the child. Our hypotheses are that prenatal exposure to EDCs and maternal overnutrition factors adversely affect child growth, adiposity, obesity and ND by mechanistic pathways (metabolomics, DNA methylation), and that maternal prenatal and child lifestyle behaviors, psychosocial factors, and child sex may moderate these effects. In Aim 3 we will maximize retention of our existing ECHO participants by implementing evidence-based strategies focused on engaging generalizable groups in clinical research and implementing the ECHO Cohort Protocol applying systematic quality control approaches and best practices. Our experienced research team includes investigators from different career stages, multiple scientific fields, geographic locations, and institutions. We are committed to providing opportunities for all members of our research team to contribute to all aspects of our proposed project and assure that they will have equal opportunity to be involved in the new ECHO phase. Our continued involvement in ECHO provides an unparalleled opportunity to further understanding of the developmental origins of child obesity and neurodevelopment and inform future interventions, prevention strategies and policies to reduce the burden of these common and costly childhood disorders and possibly their long-term impact on health across the lifespan.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $2,970,993 )
2025	2025	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	10	6/6/2025	EXTENSION WITH OR WITHOUT FUNDS	$2,970,993
														Subtotal = $2,970,993

Issue Date FY: 2024 ( Subtotal = -$276,479 )
2024	2022	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	7	4/2/2024	NON-COMPETING CONTINUATION	-$276,479
														Subtotal = -$276,479

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	7	3/15/2023	NON-COMPETING CONTINUATION	$0
2023	2022	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	001	7	4/21/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $3,964,725 )
2022	2022	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	001	7	8/31/2022	NON-COMPETING CONTINUATION	$3,964,725
2022	2021	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	6	5/6/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $3,964,725

Issue Date FY: 2021 ( Subtotal = $3,964,727 )
2021	2021	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	002	6	8/13/2021	NON-COMPETING CONTINUATION	$3,964,727
2021	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	001	5	3/30/2021	NON-COMPETING CONTINUATION	$0
2021	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	5	12/8/2020	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $3,964,727

Issue Date FY: 2020 ( Subtotal = $4,275,299 )
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	5	8/14/2020	NON-COMPETING CONTINUATION	$3,964,727
2020	2020	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	001	5	8/14/2020	SUPPLEMENT FOR EXPANSION	$310,572
														Subtotal = $4,275,299

Issue Date FY: 2019 ( Subtotal = $3,901,616 )
2019	2019	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	001	4	8/26/2019	NON-COMPETING CONTINUATION	$3,709,938
2019	2018	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	3	2/7/2019	EXTENSION WITH OR WITHOUT FUNDS	$191,678
														Subtotal = $3,901,616

Issue Date FY: 2018 ( Subtotal = $3,359,938 )
2018	2018	KAISER FOUNDATION HOSPITALS	1800 HARRISON ST FL 16	OAKLAND	CA	94612	ALAMEDA	USA	Trans-NIH Research Support	000	3	8/29/2018	EXTENSION WITH OR WITHOUT FUNDS	$3,359,938
														Subtotal = $3,359,938

Grand Total All Awards = $22,160,819

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment

Award Number: UH3OD023289

ORGANIZATION: OFFICE OF THE DIRECTOR, NIH

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/21/2016

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer